ProShare Advisors
ALLO icon

ProShare Advisors’s Allogene Therapeutics ALLO Stock Holding History

ProShare Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.8K Buy
46,070
+13,432
+41% +$29.5K ﹤0.01% 1779
2026
Q1 		$79.6K Sell
32,638
-5,396
-14% -$10.8K ﹤0.01% 1736
2025
Q4 		$52.1K Buy
38,034
+4,204
+12% +$5.54K ﹤0.01% 1949
2025
Q3 		$41.9K Sell
33,830
-5,430
-14% -$6.47K ﹤0.01% 1949
2025
Q2 		$44.4K Buy
39,260
+2,014
+5% +$2.68K ﹤0.01% 2005
2025
Q1 		$54.4K Sell
37,246
-8,836
-19% -$16.7K ﹤0.01% 1943
2024
Q4 		$98.2K Buy
46,082
+9,388
+26% +$23.2K ﹤0.01% 2080
2024
Q3 		$103K Buy
36,694
+11,149
+44% +$29.7K ﹤0.01% 1878
2024
Q2 		$59.5K Sell
25,545
-3,224
-11% -$9.51K ﹤0.01% 1726
2024
Q1 		$129K Buy
28,769
+2,377
+9% +$9.92K ﹤0.01% 1780
2023
Q4 		$84.7K Buy
26,392
+4,759
+22% +$13.5K ﹤0.01% 1803
2023
Q3 		$68.6K Buy
21,633
+1,509
+7% +$6.61K ﹤0.01% 1687
2023
Q2 		$100K Buy
20,124
+726
+4% +$3.93K ﹤0.01% 1698
2023
Q1 		$95.8K Sell
19,398
-2,783
-13% -$17.8K ﹤0.01% 1599
2022
Q4 		$140K Buy
22,181
+1,297
+6% +$12K ﹤0.01% 1582
2022
Q3 		$225K Sell
20,884
-475
-2% -$6.46K ﹤0.01% 1332
2022
Q2 		$243K Sell
21,359
-7,862
-27% -$69.8K ﹤0.01% 1343
2022
Q1 		$266K Sell
29,221
-7,554
-21% -$78.7K ﹤0.01% 1711
2021
Q4 		$549K Sell
36,775
-4,062
-10% -$71.7K ﹤0.01% 1378
2021
Q3 		$1.05M Sell
40,837
-4,639
-10% -$110K ﹤0.01% 891
2021
Q2 		$1.19M Buy
45,476
+10,365
+30% +$296K ﹤0.01% 936
2021
Q1 		$1.24M Buy
35,111
+332
+1% +$11.2K ﹤0.01% 877
2020
Q4 		$878K Buy
34,779
+4,627
+15% +$151K ﹤0.01% 944
2020
Q3 		$1.14M Buy
30,152
+2,493
+9% +$94K 0.01% 688
2020
Q2 		$1.18M Buy
27,659
+7,667
+38% +$277K 0.01% 664
2020
Q1 		$389K Sell
19,992
-12,850
-39% -$306K ﹤0.01% 796
2019
Q4 		$853K Buy
+32,842
New +$905K ﹤0.01% 851

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ProShare Advisors's ALLO Position: Q2 2026 in Review

ProShare Advisors increased its Allogene Therapeutics (ALLO) stake by 41% in Q2 2026, buying an estimated $29.5K and bringing the position to 46,070 shares worth $95.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

ProShare Advisors first reported a position in ALLO in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.24M in Q1 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • ProShare Advisors held 46,070 shares of Allogene Therapeutics worth $95.8K as of Q2 2026.
  • ProShare Advisors bought 13,432 Allogene Therapeutics shares in Q2 2026, an estimated $29.5K.
  • Allogene Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1779 holding.
  • ProShare Advisors first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • ProShare Advisors's Allogene Therapeutics position peaked at $1.24M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.